NRx Pharmaceuticals Completes Manufacturing Validation for Preservative-Free Ketamine

• NRx Pharmaceuticals completed three commercial-scale process validation lots of preservative-free ketamine, meeting FDA good manufacturing practice requirements.
• Two-year room-temperature stability testing showed no deterioration in purity, potency or sterility without preservatives.
• Commercially releasable supply is available pending FDA approval of its abbreviated new drug application, with a November 10, 2026, target date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190830PRIMZONEFULLFEED9848100) on October 19, 2026, and is solely responsible for the information contained therein.